134 related articles for article (PubMed ID: 32854646)
1. Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma.
Heiland DH; Ohle R; Cipriani D; Franco P; Delev D; Behriger SP; Kellner E; Petrova G; Neidert N; Mader I; Nuñez MF; Urbach H; Sankowski R; Beck J; Schnell O
BMC Cancer; 2020 Aug; 20(1):818. PubMed ID: 32854646
[TBL] [Abstract][Full Text] [Related]
2. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
Jiang H; Ren X; Cui X; Wang J; Jia W; Zhou Z; Lin S
Neuro Oncol; 2013 Jun; 15(6):775-82. PubMed ID: 23486687
[TBL] [Abstract][Full Text] [Related]
3. IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology.
Miyake Y; Fujii K; Nakamaura T; Ikegaya N; Matsushita Y; Gobayashi Y; Iwashita H; Udaka N; Kumagai J; Murata H; Takemoto Y; Yamanaka S; Ichimura K; Tateishi K; Yamamoto T
J Neuropathol Exp Neurol; 2021 Feb; 80(3):247-253. PubMed ID: 33432322
[TBL] [Abstract][Full Text] [Related]
4. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
5. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
Andrews C; Prayson RA
Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
[TBL] [Abstract][Full Text] [Related]
6. Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.
Kanamori M; Kumabe T; Shibahara I; Saito R; Yamashita Y; Sonoda Y; Suzuki H; Watanabe M; Tominaga T
Brain Tumor Pathol; 2013 Jul; 30(3):151-9. PubMed ID: 23053495
[TBL] [Abstract][Full Text] [Related]
7. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.
Sathornsumetee S; Cheunsuchon P; Sangruchi T
World Neurosurg; 2016 Jul; 91():518-523.e1. PubMed ID: 26960282
[TBL] [Abstract][Full Text] [Related]
8. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
[TBL] [Abstract][Full Text] [Related]
9. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
10. Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.
Johnson DR; Diehn FE; Giannini C; Jenkins RB; Jenkins SM; Parney IF; Kaufmann TJ
AJNR Am J Neuroradiol; 2017 Apr; 38(4):678-684. PubMed ID: 28126746
[TBL] [Abstract][Full Text] [Related]
11. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
[TBL] [Abstract][Full Text] [Related]
12. MR textural analysis on T
Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z
J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606
[TBL] [Abstract][Full Text] [Related]
13. Rare occurrence of IDH2 mutation in adolescent oligodendroglioma with 1p/19q co-deletion: a case report.
Rao S; Sivakoti S; Arivazhagan A; Santosh V
Childs Nerv Syst; 2020 Dec; 36(12):3109-3113. PubMed ID: 32296936
[TBL] [Abstract][Full Text] [Related]
14. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
[TBL] [Abstract][Full Text] [Related]
15. Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism.
Vaubel RA; Kollmeyer TM; Caron AA; Barr Fritcher EG; Voss JS; Liang H; Jenkins RB; Giannini C; Kipp BR
Acta Neuropathol; 2017 Aug; 134(2):317-319. PubMed ID: 28550371
[No Abstract] [Full Text] [Related]
16. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
[TBL] [Abstract][Full Text] [Related]
17. Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.
Lin AL; Liu J; Evans J; Leuthardt EC; Rich KM; Dacey RG; Dowling JL; Kim AH; Zipfel GJ; Grubb RL; Huang J; Robinson CG; Simpson JR; Linette GP; Chicoine MR; Tran DD
Neuro Oncol; 2014 Jan; 16(1):123-30. PubMed ID: 24285548
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of molecular analysis in diffuse glioma stratification.
Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
[TBL] [Abstract][Full Text] [Related]
19. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.
Reyes-Botero G; Dehais C; Idbaih A; Martin-Duverneuil N; Lahutte M; Carpentier C; Letouzé E; Chinot O; Loiseau H; Honnorat J; Ramirez C; Moyal E; Figarella-Branger D; Ducray F;
Neuro Oncol; 2014 May; 16(5):662-70. PubMed ID: 24353325
[TBL] [Abstract][Full Text] [Related]
20. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S
Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710
[No Abstract] [Full Text] [Related]
[Next] [New Search]
